title: Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
abstract: The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit from a specific treatment. Despite more than two decades of research into the molecular genetics of colon cancer, there is a lack of prognostic and predictive molecular biomarkers with proven utility in this setting. A secondary objective of the Pan European Trials in Adjuvant Colon Cancer-3 trial, which compared irinotecan in combination with 5-fluorouracil and leucovorin in the postoperative treatment of stage III and stage II colon cancer patients, was to undertake a translational research study to assess a panel of putative prognostic and predictive markers in a large colon cancer patient cohort. The Cancer and Leukemia Group B 89803 trial, in a similar design, also investigated the use of prognostic and predictive biomarkers in this setting. In this article, the authors, who are coinvestigators from these trials and performed similar investigations of biomarker discovery in the adjuvant treatment of colon cancer, review the current status of biomarker research in this field, drawing on their experiences and considering future strategies for biomarker discovery in the postgenomic era.
authors.affiliation: Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. sabine.tejpar@uz.kuleuven.ac.be
authors.forename: Sabine
authors.initials: S
authors.lastname: Tejpar
authors.forename: Monica
authors.initials: M
authors.lastname: Bertagnolli
authors.forename: Fred
authors.initials: F
authors.lastname: Bosman
authors.forename: Heinz-Joseph
authors.initials: HJ
authors.lastname: Lenz
authors.forename: Levi
authors.initials: L
authors.lastname: Garraway
authors.forename: Frederic
authors.initials: F
authors.lastname: Waldman
authors.forename: Robert
authors.initials: R
authors.lastname: Warren
authors.forename: Andrea
authors.initials: A
authors.lastname: Bild
authors.forename: Denise
authors.initials: D
authors.lastname: Collins-Brennan
authors.forename: Hejin
authors.initials: H
authors.lastname: Hahn
authors.forename: D Paul
authors.initials: DP
authors.lastname: Harkin
authors.forename: Richard
authors.initials: R
authors.lastname: Kennedy
authors.forename: Mohammad
authors.initials: M
authors.lastname: Ilyas
authors.forename: Hans
authors.initials: H
authors.lastname: Morreau
authors.forename: Vitali
authors.initials: V
authors.lastname: Proutski
authors.forename: Charles
authors.initials: C
authors.lastname: Swanton
authors.forename: Ian
authors.initials: I
authors.lastname: Tomlinson
authors.forename: Mauro
authors.initials: M
authors.lastname: Delorenzi
authors.forename: Roberto
authors.initials: R
authors.lastname: Fiocca
authors.forename: Eric
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: Arnaud
authors.initials: A
authors.lastname: Roth
mesh_terms: D014408:Biomarkers, Tumor; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D018450:Disease Progression; D016158:Genes, p53 / Q000235:genetics; D042822:Genomic Instability; D023281:Genomics; D006801:Humans; D053842:Microsatellite Instability; D010641:Phenotype; D011237:Predictive Value of Tests; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins